- Home
- HAYW vs MLTX Comparison
HAYW vs MLTX Comparison
Compare HAYW & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- MLTX
- Stock Information
- Founded
- HAYW 1925
- MLTX 2021
- Country
- HAYW United States
- MLTX Switzerland
- Employees
- HAYW N/A
- MLTX N/A
- Industry
- HAYW Electronic Components
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- HAYW Technology
- MLTX Health Care
- Exchange
- HAYW Nasdaq
- MLTX Nasdaq
- Market Cap
- HAYW 2.9B
- MLTX 2.8B
- IPO Year
- HAYW 2021
- MLTX N/A
- Fundamental
- Price
- HAYW $14.20
- MLTX $48.89
- Analyst Decision
- HAYW Hold
- MLTX Strong Buy
- Analyst Count
- HAYW 5
- MLTX 7
- Target Price
- HAYW $16.83
- MLTX $73.33
- AVG Volume (30 Days)
- HAYW 1.8M
- MLTX 504.0K
- Earning Date
- HAYW 07-29-2025
- MLTX 08-06-2025
- Dividend Yield
- HAYW N/A
- MLTX N/A
- EPS Growth
- HAYW 51.32
- MLTX N/A
- EPS
- HAYW 0.56
- MLTX N/A
- Revenue
- HAYW $1,067,878,000.00
- MLTX N/A
- Revenue This Year
- HAYW $5.27
- MLTX $103.42
- Revenue Next Year
- HAYW $5.51
- MLTX N/A
- P/E Ratio
- HAYW $25.37
- MLTX N/A
- Revenue Growth
- HAYW 7.34
- MLTX N/A
- 52 Week Low
- HAYW $11.10
- MLTX $31.42
- 52 Week High
- HAYW $16.87
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- HAYW 56.89
- MLTX 66.20
- Support Level
- HAYW $13.63
- MLTX $46.24
- Resistance Level
- HAYW $14.58
- MLTX $48.72
- Average True Range (ATR)
- HAYW 0.37
- MLTX 1.54
- MACD
- HAYW 0.05
- MLTX 0.16
- Stochastic Oscillator
- HAYW 72.73
- MLTX 94.34
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.